44 related articles for article (PubMed ID: 9818037)
1. Prolactinomas in male and female patients: a comparative clinicopathologic study.
Calle-Rodrigue RD; Giannini C; Scheithauer BW; Lloyd RV; Wollan PC; Kovacs KT; Stefaneanu L; Ebright AB; Abboud CF; Davis DH
Mayo Clin Proc; 1998 Nov; 73(11):1046-52. PubMed ID: 9818037
[TBL] [Abstract][Full Text] [Related]
2. Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.
Dzialach L; Sobolewska J; Zak Z; Respondek W; Witek P
Front Endocrinol (Lausanne); 2024; 15():1338345. PubMed ID: 38370355
[TBL] [Abstract][Full Text] [Related]
3. Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma.
Rudman Y; Duskin-Bitan H; Masri-Iraqi H; Akirov A; Shimon I
Pituitary; 2022 Dec; 25(6):882-890. PubMed ID: 36036309
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study.
Bima C; Chiloiro S; Giampietro A; Gessi M; Mattogno PP; Lauretti L; Anile C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
Front Endocrinol (Lausanne); 2021; 12():684055. PubMed ID: 34322092
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging in the management of prolactinomas; a review of the evidence.
Varlamov EV; Hinojosa-Amaya JM; Fleseriu M
Pituitary; 2020 Feb; 23(1):16-26. PubMed ID: 31659622
[TBL] [Abstract][Full Text] [Related]
6. Pathology of prolactinomas: any predictive value?
Lopes MBS
Pituitary; 2020 Feb; 23(1):3-8. PubMed ID: 31641970
[TBL] [Abstract][Full Text] [Related]
7. Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability.
Wierinckx A; Delgrange E; Bertolino P; François P; Chanson P; Jouanneau E; Lachuer J; Trouillas J; Raverot G
Front Endocrinol (Lausanne); 2018; 9():706. PubMed ID: 30555413
[TBL] [Abstract][Full Text] [Related]
8. Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.
Iglesias P; Rodríguez Berrocal V; Díez JJ
Endocrine; 2018 Sep; 61(3):407-421. PubMed ID: 29909598
[TBL] [Abstract][Full Text] [Related]
9. Management of macroprolactinomas.
Tirosh A; Shimon I
Clin Diabetes Endocrinol; 2015; 1():5. PubMed ID: 28702224
[TBL] [Abstract][Full Text] [Related]
10. Cancer in Transgender People: Evidence and Methodological Considerations.
Braun H; Nash R; Tangpricha V; Brockman J; Ward K; Goodman M
Epidemiol Rev; 2017 Jan; 39(1):93-107. PubMed ID: 28486701
[TBL] [Abstract][Full Text] [Related]
11. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
12. Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.
Shimon I; Benbassat C; Tzvetov G; Grozinsky-Glasberg S
Pituitary; 2011 Mar; 14(1):11-5. PubMed ID: 20717729
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of MIB-1 labeling index in pituitary adenomas.
Chacko G; Chacko AG; Kovacs K; Scheithauer BW; Mani S; Muliyil JP; Seshadri MS
Pituitary; 2010 Dec; 13(4):337-44. PubMed ID: 20640601
[TBL] [Abstract][Full Text] [Related]
14. Prolonged oestrogen treatment does not correlate with a sustained increase in anterior pituitary mitotic index in ovariectomized Wistar rats.
Nolan LA; Levy A
J Endocrinol; 2009 Mar; 200(3):301-9. PubMed ID: 19106235
[TBL] [Abstract][Full Text] [Related]
15. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
16. PRL secreting adenomas in male patients.
Ciccarelli A; Guerra E; De Rosa M; Milone F; Zarrilli S; Lombardi G; Colao A
Pituitary; 2005; 8(1):39-42. PubMed ID: 16411067
[TBL] [Abstract][Full Text] [Related]
17. The epidemiology of prolactinomas.
Ciccarelli A; Daly AF; Beckers A
Pituitary; 2005; 8(1):3-6. PubMed ID: 16411062
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
Chattopadhyay A; Bhansali A; Masoodi SR
Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
[TBL] [Abstract][Full Text] [Related]
19. Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.
Knoepfelmacher M; Gomes MC; Melo ME; Mendonca BB
Pituitary; 2004; 7(2):83-7. PubMed ID: 15761656
[TBL] [Abstract][Full Text] [Related]
20. Hyperprolactinemia in men: clinical and biochemical features and response to treatment.
De Rosa M; Zarrilli S; Di Sarno A; Milano N; Gaccione M; Boggia B; Lombardi G; Colao A
Endocrine; 2003; 20(1-2):75-82. PubMed ID: 12668871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
